|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The results demonstrated that: i) PCPH is expressed in TGCT cell lines and tumors, including CIS; ii) its expression levels vary among different TGCT pathologies, being generally higher in well differentiated regions and lower in areas of predominant proliferation; iii) PCPH expression is substantially increased in tumors relative to matched normal testicular tissue; iv) tumor samples express PCPH polypeptides of low molecular mass, consistent with the known size of the PCPH oncoprotein, that are either absent from, or markedly reduced in, matched normal tissue.
|
16465363 |
2006 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Furthermore, the detection of atypical PCPH polypeptides in tumors suggests that PCPH immunodetection may be applied as a diagnostic tool for the early identification of neoplastic breast epithelial cells.
|
11933075 |
2002 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Additionally, an upregulation of ENTPD5 in both GBM mouse xenografts and in GBM patient tumors was identified, resulting in dramatically reduced survival.
|
22992974 |
2012 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Suppression of ENTPD5 is sufficient to decrease IGF-IR levels and sensitize bronchiolar tumor cells to serum in vitro and to dietary restriction in vivo.
|
23719831 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Expression of the Protein Product of the PCPH Proto-oncogene in Human Tumor Cell Lines.
|
11121232 |
2001 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Understanding possible alternative mechanisms will be essential to devise strategies for the successful treatment of predictably therapeutically resistant tumors expressing either increased PCPH levels or, particularly, the mt-PCPH oncoprotein.
|
23921441 |
2013 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our previous studies on the involvement of PCPH in human cancer showed that human breast tumor cell lines have frequent alterations in PCPH, including multiple PCPH polypeptide forms that are not expressed in normal cells.
|
11933075 |
2002 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Recently, the endoplasmic reticulum UDPase, ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), was identified as a key component in the Akt/phosphatidylinositol 3-kinase/phosphatase and tensin homolog regulatory loop, capable of synergizing aerobic glycolysis and cancer cell proliferation in vitro.
|
22992974 |
2012 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Several studies analyzed the expression of NTPDase5/mt-PCPH in a wide range of tumor cells and evaluated its role and mechanisms in cancer and other pathogenic processes.
|
25045656 |
2014 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ENTPD5 supports cancer growth by promoting the import of UDP-glucose, a metabolite used for protein glycosylation and hence proper glycoprotein folding, into the ER by providing the counter molecule, UMP, to the ER antiporter.
|
31242188 |
2019 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
A comprehensive pan-cancer analysis revealed a highly significant correlation between p53 GOF mutations and ENTPD5 expression.
|
27956623 |
2016 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Several studies analyzed the expression of NTPDase5/mt-PCPH in a wide range of tumor cells and evaluated its role and mechanisms in cancer and other pathogenic processes.
|
25045656 |
2014 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
ENTPD5 supports cancer growth by promoting the import of UDP-glucose, a metabolite used for protein glycosylation and hence proper glycoprotein folding, into the ER by providing the counter molecule, UMP, to the ER antiporter.
|
31242188 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
GeneticVariation
|
group |
BEFREE |
A comprehensive pan-cancer analysis revealed a highly significant correlation between p53 GOF mutations and ENTPD5 expression.
|
27956623 |
2016 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Our previous studies on the involvement of PCPH in human cancer showed that human breast tumor cell lines have frequent alterations in PCPH, including multiple PCPH polypeptide forms that are not expressed in normal cells.
|
11933075 |
2002 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Recently, the endoplasmic reticulum UDPase, ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), was identified as a key component in the Akt/phosphatidylinositol 3-kinase/phosphatase and tensin homolog regulatory loop, capable of synergizing aerobic glycolysis and cancer cell proliferation in vitro.
|
22992974 |
2012 |
|
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism.
|
18006831 |
2007 |
|
Prostatic Neoplasms
|
0.020 |
Biomarker
|
group |
LHGDN |
PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.
|
19117992 |
2009 |
|
Laryngeal Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This trend toward loss of PCPH expression along malignant progression of the larynx was confirmed by the low to null expression of PCPH in samples of invasive laryngeal carcinoma and by the complete absence of PCPH immunostaining in a laryngeal carcinoma-derived liver metastasis.
|
12489110 |
2002 |
|
Neoplasms, Germ Cell and Embryonal
|
0.010 |
Biomarker
|
group |
LHGDN |
PCPH expression is an early event in the development of testicular germ cell tumors.
|
16465363 |
2006 |
|
Testicular Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Collectively, these results positively identify PCPH as a good early molecular marker for testicular neoplasms, and strongly indicate that immunodetection of truncated PCPH polypeptides may be a useful diagnostic tool for TGCT.
|
16465363 |
2006 |
|
Testicular Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Collectively, these results positively identify PCPH as a good early molecular marker for testicular neoplasms, and strongly indicate that immunodetection of truncated PCPH polypeptides may be a useful diagnostic tool for TGCT.
|
16465363 |
2006 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our previous studies on the involvement of PCPH in human cancer showed that human breast tumor cell lines have frequent alterations in PCPH, including multiple PCPH polypeptide forms that are not expressed in normal cells.
|
11933075 |
2002 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Our results strengthen the hypothesis of a central role of miR-182 dysregulation in colon mucosa transformation, demonstrate the concomitant progressive down-regulation of ENTPD5 levels during colon carcinogenesis, and indicate the potential of circulating miR-182 as blood based biomarker for screening and monitoring CRC during the follow-up.
|
25115394 |
2014 |